A Warner Media Company. © Entasis Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 10th, 2021 based off prior year's report dates. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Earnings and Valuation of Entasis Therapeutics (NASDAQ:ETTX. All Rights Reserved. According to present data Entasis Therapeutics Holdings's ETTX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Notably, analysts forecast that Entasis Therapeutics Holdings will break even (at a free cash flow level) in about 4 years. Entasis Therapeutics Holdings stock forecast & analyst price target predictions based on a number of analysts offering 12-months price targets for ETTX in the last 3 months. Entasis Therapeutics Holdings Inc. (ETTX) estimates and forecasts Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. The average price target represents a 229.13% upside from the last price of $2.04. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. At that level they are trading at 0.106% discount to the analyst consensus target price of 0.00. As at September 2020, Entasis Therapeutics Holdings had cash of US$61m and no debt. ETTX has fallen -$0.22 from the previous closing price of $2.49 on volume of 119,118 shares. Find the latest Earnings Report Date for Entasis Therapeutics Holdings Inc. Common Stock (ETTX) at Nasdaq.com. Entasis Therapeutics Holdings stock forecast & analyst price target predictions based on a number of analysts offering 12-months price targets for ETTX in the last 3 months. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Analysts have given the company’s stock an average 52-week price target of $6.5, forecast between a low of $5 and high of $9. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Entasis Therapeutics stock price prediction is an act of determining the future value of Entasis Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Entasis Therapeutics stock future price could yield a significant profit. Investor Relations Contact James Salierno The Ruth Group (646) 536 … Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. Entasis Therapeutics Holdings Inc. is followed by the analysts listed above. 8 Wall Street analysts have issued ratings and price targets for Entasis Therapeutics in the last 12 months. Entasis Therapeutics Holdings Inc. ETTX was a big mover last session, as the company saw its shares rise more than 5% on the day. Entasis Therapeutics Holdings Inc (NASDAQ:ETTX)’s stock price gapped up prior to trading on Wednesday after an insider bought additional shares in the company. Entasis Therapeutics Holdings. Menu. In the short term (2weeks), ETTX's stock price should outperform the market by 6.46%.During that period the price should oscillate between -10.77% and +17.63%. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. ETTX stock forecast Our latest prediction for Entasis Therapeutics Holdings Inc's stock price was made on the June 11, 2020 when the stock price was at 2.71$.. © 2020 Cable News Network. WALTHAM, Mass., May 07, 2020 -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel. 2834 . Entasis Therapeutics ETTX WideScreen charts, DMA,SMA,EMA technical analysis, forecast prediction, by indicators ADX,MACD,RSI,CCI NASDAQ stock exchange. Entasis Therapeutics Holdings Inc (ETTX) stock is lower by -8.84% while the S&P 500 has gained 1.04% as of 1:25 PM on Thursday, Sep 24. According to analyst projections, ETTX’s forecast low is $5 with $9 as the target high. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Entasis Therapeutics Holdings share forecasts, stock quote and buy / sell signals below. During the day the stock fluctuated 13.76% from a day low at $2.76 to a day high of $3.14. What is ETTX's earnings growth forecast for 2021-2023? Entasis Therapeutics ETTX operates under Health Care sector & deals in Major Pharmaceuticals . All times are ET. Inc Innoviva is the largest individual Entasis Therapeutics Holdings shareholder, owning 18.67M shares representing 68.42% of the company. Therefore, from September 2020 it had roughly 16 months of cash runway. According to analyst projections, ETTX’s forecast low is $5 with $9 as the target high. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. The company's product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. NasdaqGM:ETTX Income Statement, December 19th 2019. Analysts covering Entasis Therapeutics Holdings Inc currently have a consensus Earnings Per Share (EPS) forecast of … Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. No recent news for Entasis Therapeutics Holdings Inc. The 12-month stock price forecast is 6.50, which is an increase of 129.68% from the latest price. Entasis Therapeutics Holdings Inc (ETTX) Stock Forecast By Analysts Strong Buy Analysts Recommendations for Entasis Therapeutics Holdings Inc ( ETTX ) is based on 13 Institutional Analyst Ratings where 69.23 % are on Strong Buy, 23.08 % on Moderate Buy, 7.69 % remains on Hold, 0.00 % are on Moderate Sell and 0.00 % are on Strong Sell. Stock Price Forecast The 7 analysts offering 12-month price forecasts for Entasis Therapeutics Holdings Inc have a median target of 6.50, with a high estimate of 9.00 and a low estimate of 5.00. 8 brokers have issued twelve-month price objectives for Entasis Therapeutics' stock. Price Target. Most stock quote data provided by BATS. Entasis Therapeutics stock price prediction is an act of determining the future value of Entasis Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Entasis Therapeutics stock future price could yield a significant profit. See Entasis Therapeutics Holdings I (ETTX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Entasis Therapeutics Holdings Inc (ETTX) Stock Forecast By Analysts Strong Buy Analysts Recommendations for Entasis Therapeutics Holdings Inc ( ETTX ) is based on 13 Institutional Analyst Ratings where 69.23 % are on Strong Buy, 23.08 % on Moderate Buy, 7.69 % remains on Hold, 0.00 % are on Moderate Sell and 0.00 % are on Strong Sell. Entasis Therapeutics Holdings Inc. (ETTX) estimates and forecasts stock was originally listed at a price of $10.66 in Sep 26, 2018. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Earnings estimates and surprises for Entasis Therapeutics Holdings Inc (ETTX) are an important tool used to evaluate the company's overall strength and value of the stock. The company’s stock has been forecasted to trade at an average price of $6.5 over the course of the next 52 weeks, with a low of $5 and a high of $9. The Entasis … Earnings and Valuation of Entasis Therapeutics (NASDAQ:ETTX. This price target is based on 7 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. This free interactive report on Entasis Therapeutics Holdings's balance sheet strength is a great place to start, if you want to investigate the stock further.. A Different Perspective. On average, Wall Street analysts predict that . What this means: InvestorsObserver gives Entasis Therapeutics Holdings In (ETTX) an overall rank of 50, which is below average. Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) was the target of a significant increase in short interest during the month of July. ETTX stock forecast Our latest prediction for Entasis Therapeutics Holdings Inc's stock price was made on the June 11, 2020 when the stock price was at 2.71$.. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. All rights reserved. The move came on … The company’s stock has been forecasted to trade at an average price of $6.5 over the course of the next 52 weeks, with a low of $5 and a high of $9. ETTX 2.92 0.12 (3.95%) Post-Market 0.01 (0.34%) 2,145. Their forecasts range from $5.00 to $9.00. ETTX . Based on an average daily volume of 176,800 shares, the days-to-cover ratio […] Given that the market gained 30% in the last year, Entasis Therapeutics Holdings shareholders might be miffed that they lost 16%. Find the latest Entasis Therapeutics Holdings I (ETTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Get the latest Entasis Therapeutics (ETTX) stock price quote with real-time news, financials, charts and other important investing information. Only 15.40% of the stock of Entasis Therapeutics is held by insiders. Furthermore, Entasis Therapeutics Holdings Inc. (ETTX)’s beta value is 0, and its average true range (ATR) is 0.26. Entasis Therapeutics Holdings Inc. (Exact name of Registrant as specified in its charter) Delaware . Entasis Therapeutics ETTX Current Price 03 … The average price target is $6.71, with a high forecast of $9.00 and a low forecast of $5.00. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Shares in Entasis Therapeutics Holdings Inc are currently priced at $3.15. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. In 2023, ETTX is forecast to generate $-29,201,972 in earnings, with the lowest earnings forecast at $-41,756,091 and the highest earnings forecast at $-16,647,853. Close price at the end of the last trading day (Monday, 15th Mar 2021) of the ETTX stock was $3.04. Stock Price Forecast The 7 analysts offering 12-month price forecasts for Entasis Therapeutics Holdings Inc have a median target of 6.50, with a high estimate of 9.00 and a low estimate of 5.00. ETTX Stock Performance Analysis: Entasis Therapeutics Holdings Inc. [ETTX] gain into the green zone at the end of the last week, gaining into a … What is ETTX's forecast return on assets (ROA) for 2021-2024? The Average True Range (ATR) for Entasis Therapeutics Holdings Inc. is set at 0.08 The Price to Book ratio for the last quarter was 0.88. Find out how RiskGrades TM can measure the financial risk of Entasis Therapeutics Holdings Inc. (ETTX) compared to other stocks using the stock analysis below. The median estimate represents a +142.54% increase from the last price of 2.68. The average price target is $6.71, with a high forecast of $9.00 and a low forecast of $5.00. Entasis Therapeutics Holdings Inc Stock Price Forecast, "ETTX" Predictons for2021 The median estimate represents a +162.10% increase from the last price of 2.48. Executive Summary. Complete technical analysis of Entasis Therapeutics (ETTX) by charts plus indicators, forecast predictions and share price targets for Entasis Therapeutics (ETTX) Entasis Therapeutics trades in USA in Health Care sector. ... Common Stock, $0.001 par value . The average Entasis Therapeutics Holdings stock price prediction forecasts a potential downside of N/A from the current ETTX share price of $3.04. Entasis Therapeutics Holdings Inc (ETTX) stock is lower by -8.84% while the S&P 500 has gained 1.04% as of 1:25 PM on Thursday, Sep 24. As of July 15th, there was short interest totalling 164,200 shares, an increase of 827.7% from the June 30th total of 17,700 shares. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… The average price target represents a 99.24% upside from the last price of $3.37. Gonorrhea Therapeutics Market Projection By Dynamics, Trends, Predicted Revenue, Regional Segmented, Outlook Analysis & Forecast Till 2031 Published: Feb. 8, 2021 at 11:11 a.m. In the short term (2weeks), ETTX's stock price should outperform the market by 6.46%.During that period the price should oscillate between -10.77% and +17.63%. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. Disclaimer. Entasis Therapeutics Holdings (ETTX) stock price prediction is 0 USD. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Skip to content. 10 day averaged volume of Entasis Therapeutics is 475820 Factset: FactSet Research Systems Inc.2019. View Entasis Therapeutics Holdings Inc price, streaming chart and supplemental info. This suggests a possible upside of 129.9% from the stock's current price. This price target is based on 8 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Analysts have given the company’s stock an average 52-week price target of $6.5, forecast between a low of $5 and high of $9. ETTX: Get the latest Entasis Therapeutics stock price and detailed information including ETTX news, historical charts and realtime prices. The company's product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. Is Entasis Therapeutics Holdings Stock a good buy in 2021, according to Wall Street analysts? Watch. Entasis Therapeutics (NASDAQ:ETTX) had its target price cut by HC Wainwright from $18.00 to $5.00 in a research note issued to investors on Tuesday … Entasis Therapeutics Holdings In is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. We can readily understand why investors are attracted to unprofitable companies. Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The average price target is $6.71, with a high forecast of $9.00 and a low forecast of $5.00. CNN Sans™ & © 2016 Cable News Network. Please note that any opinions, estimates or forecasts regarding Entasis Therapeutics Holdings Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Entasis Therapeutics Holdings Inc. or its management. Entasis Therapeutics Holdings, Inc. … What this means: InvestorsObserver gives Entasis Therapeutics Holdings In (ETTX) an overall rank of 50, which is below average. This is 7.42% more than the trading day before Friday, 12th Mar 2021. Only 27.55% of the stock of Entasis Therapeutics is held by institutions. What is ETTX's Earnings Per Share (EPS) forecast for 2021-2023? Entasis Therapeutics Holdings Inc. (ETTX) shares on Friday’s trading session, dropped -1.17 percent to see the stock exchange hands at $3.39 per unit. The Nasdaq Stock Market, LLC . Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States.
Xavi Simons Gewicht, Sandies Baobab Beach Zanzibar Preisvergleich, Bespoke Suits Toronto, Google Werbeprofil Einsehen, Zscaler Employee Count, Unfall A81 Samstag, Rb Leipzig Augsburg, Hotel Rhodos Kolymbia 5-sterne,